Xian Janssen Pharmaceutical Ltd. welcomes inclusion of IMBRUVICA® (ibrutinib capsules) for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) and REMICADE® (injected infliximab) for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis, Crohn’s Disease and psoriasis on the Reimbursement List for Drugs Treating Major Illnesses in Zhejiang Province. Inclusion of IMBRUVICA® comes just 50 days after its launch in China, while REMICADE® has now been added for a second time.
Listing of IMBRUVICA® and REMICADE®, together with their reimbursement through insurance in Zhejiang Province, recognizes the efficacy of these treatments and will significantly reduce the burden for patients in China living with these conditions.
As a Company, we are committed to developing innovative medicines that enhance patient outcomes. We will continue to work closely with Healthcare Authorities to support access to our medicines for those patients most in need.
This new regulation is effective January 1, 2018.
For more information, please see the notification on the Zhejiang Province Human Resources and Social Security Department’s website: http://www.zjhrss.gov.cn/art/2018/1/16/art_1442999_9237.html